Name the product, then pivot to the record that reframes it. The story of augmented reality has always been told through consumer hardware — glasses, headsets, the promise of digital overlays on daily life. But read the 2020 grant record and the center of gravity is somewhere else entirely. US10861236B2, a "Dual mode augmented reality surgical system" granted to Surgical Theater on December 8, 2020, and US10642046B2, "Augmented reality systems for time critical biomedical applications" granted to Cloud DX on May 5, 2020, both sit at the intersection of headset optics and medicine.
The classifications are the evidence. Both patents carry G02B 27/0172, the head-mounted-display optics class that any consumer headset would also use. But both also carry medical classes — A61B for diagnostic and surgical apparatus, G16H for health informatics, G06T 19/006 for AR rendering of medical imagery. That pairing is the signature of a device built to do real clinical work, where a heads-up overlay of a patient's anatomy has measurable value a consumer overlay does not.
What it costs, what it earns, who owns it. A surgical AR system can justify a five-figure price tag because it sits in a reimbursement-backed workflow; a consumer headset has to fight for a few hundred dollars of discretionary spend. The economics explain why the early grant clusters are clinical. The hard optics were the same, but the willingness to pay was not.
This is the kind of pattern the consumer-tech press routinely misses because it does not read the docket. The headlines in 2020 were about consumer AR glasses that kept not arriving. The grants were about AR finding paying customers in operating rooms and remote diagnostics — the unglamorous use cases that funded the optics work.
Scope and posture, stated plainly: these are granted patents to specialized firms, not to the consumer platforms. They do not tell you Apple's or Meta's strategy. What they tell you is where the technology found a market first, which is itself a strategic signal — the optics matured on someone else's clinical revenue.
Follow the filing. When consumer AR finally ships at scale, it will ride on optics and rendering techniques that were paid for, in part, by medicine. The 2020 docket is where that subsidy is visible.